Ann Dermatol.  2014 Feb;26(1):137-138. 10.5021/ad.2014.26.1.137.

Myocardial Infarction in a Patient Treated with Anti-Interleukin-12 Biological Agent for Chronic Plaque Psoriasis

• Stinco G
• Buligan C
• Bergamo S
• Morgante O
• Iacono MA
• Patrone P

• KMID: 2265720
• DOI: http://doi.org/10.5021/ad.2014.26.1.137

Abstract

No abstract available.

MeSH Terms

Humans
Myocardial Infarction*
Psoriasis*

Reference

1. Taleb S, Tedgui A, Mallat Z. Adaptive T cell immune responses and atherogenesis. Curr Opin Pharmacol. 2010; 10:197–202.

2. Puig L. Cardiovascular risk and psoriasis: the role of biologic therapy. Actas Dermosifiliogr. 2012; 103:853–862.

3. Reich K, Langley RG, Lebwohl M, Szapary P, Guzzo C, Yeilding N, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol. 2011; 164:862–872.

4. Ryan C, Leonardi CL, Krueger JG, Kimball AB, Strober BE, Gordon KB, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011; 306:864–871.

5. Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2013; 27:622–627.